Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 2/20 | 0.60 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 3/20 | 0.49 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.46 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4661300 | 1.00 | CRHBP (0.60) | CRHBPCRHR2KDM4ELMNAKMT2A | |
| SCHEMBL28895520 | 0.88 | CRHBP (0.55) | CRHBPCRHR2KDM4ELMNAKMT2A | |
| SCHEMBL38660761 | 0.86 | KMT2A (0.54) | CRHBPCRHR2KDM4ELMNAKMT2A | |
| SCHEMBL10609933 | 0.86 | KDM4E (0.54) | CRHBPCRHR2KDM4ELMNAKMT2A | |
| SCHEMBL9027589 | 0.86 | MCL1 (0.57) | CRHBPCRHR2KDM4ELMNAKMT2A | |
| SCHEMBL27944197 | 0.84 | EGFR (0.61) | CRHBPCRHR2KDM4ELMNAKMT2A | |
| SCHEMBL8830506 | 0.83 | CRHBP (0.53) | CRHBPCRHR2KDM4ELMNAKMT2A | |
| SCHEMBL8830501 | 0.83 | CRHBP (0.53) | CRHBPCRHR2KDM4ELMNAKMT2A | |
| SCHEMBL14603500 | 0.83 | POLB (0.47) | CRHBPCRHR2KDM4ELMNAKMT2A | |
| SCHEMBL13938656 | 0.83 | POLB (0.64) | KDM4ELMNAKMT2APKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9752049-B2 | Optically transparent, superhydrophobic, biocompatible thin film coatings and methods for producing same | UT-BATTELLE, LLC (US) | 2017-09-05 | — | — | US | claimed |
| US-20150232690-A1 | OPTICALLY TRANSPARENT, SUPERHYDROPHOBIC, BIOCOMPATIBLE THIN FILM COATINGS AND METHODS FOR PRODUCING SAME | UT-BATTELLE, LLC (US) | 2015-08-20 | — | — | US | claimed |
| EP-1360257-B1 | CYANOACRYLATE COMPOSITIONS CURABLE TO FLEXIBLE POLYMERIC MATERIALS | LOCTITE R & D LTD (IE) | 2007-07-25 | — | — | EP | claimed |
| CN-103709069-A | 6'-hydroxyl naphthyl-2-cyanoacrylate and application thereof | UNIV SOUTHERN MEDICAL | 2014-04-09 | — | — | CN | disclosed |
| EP-1620102-B1 | 3-(1-NAPHTHYL)-2-CYANOPROPANOIC ACID DERIVATIVES AS ESTROGEN RECEPTOR LIGANDS | WYETH CORP (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20070299105-A1 | 2-Cyanopropanoic Acid Amide and Ester Derivatives and Methods of Their Use | WYETH (US) | 2007-12-27 | — | — | US | disclosed |
| EP-1620102-A2 | 3-(1-NAPHTHYL)-2-CYANOPROPANOIC ACID DERIVATIVES AS ESTROGEN RECEPTOR LIGANDS | Wyeth (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20050256132-A1 | Use of ER selective NF-kB inhibitors for the treatment of sepsis | WYETH (US) | 2005-11-17 | — | — | US | disclosed |
| US-20050004164-A1 | 2-Cyanopropanoic acid amide and ester derivatives and methods of their use | WYETH | 2005-01-06 | — | — | US | disclosed |
| WO-2004099150-A2 | 3-(1-NAPHTHYL)-2-CYANOPROPANOIC ACID DERIVATIVES AS ESTROGEN RECEPTOR LIGANDS | WYETH (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256132-A1 | Use of ER selective NF-kB inhibitors for the treatment of sepsis | NFKBIA, IKBKB, NFKB2 | CRHBP 295/4885CRHR2 628/4885KDM4E 1711/4885 |
| US-20070299105-A1 | 2-Cyanopropanoic Acid Amide and Ester Derivatives and Methods of Their Use | HCAR2, PCCA, MCCC2 | CRHBP 1939/4885CRHR2 705/4885KDM4E 2551/4885 |
| US-20050004164-A1 | 2-Cyanopropanoic acid amide and ester derivatives and methods of their use | HCAR2, PCCA, MCCC2 | CRHBP 1690/4885CRHR2 615/4885KDM4E 2836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.